HEALTH (ALT)

KWN HEALTH

HEALTH (MSM)

Eisai drug extends survival in patients with rare cancers

A drug made by Japan’s Eisai Co that was originally derived from sea sponges helped extend lives of patients with soft-tissue cancers known as sarcomas by two months, a significant advance for these rare cancers with few treatment options, Belgian researchers said on Saturday. The researchers studied the drug, known as eribulin, in 452 patients with two forms of sarcomas – leiomyosarcoma, which starts in smooth muscles, and adipocytic sarcoma,

J&J multiple myeloma drug offers hope after others stop working: study

An experimental biotech drug being developed by Johnson & Johnson may offer hope to multiple myeloma patients who have run out of options, according to data from a midstage study released at a cancer meeting on Saturday. J&J plans to use the Phase II study to seek U.S. and European approval of its antibody daratumumab to treat the blood cancer. The drug received breakthrough designation from the U.S. Food and

New research shows immunotherapy targeting several cancers

Immunotherapy, which has shown remarkable success against advanced melanoma skin cancers, is now being used to target other cancers that are tough to treat. The results of several clinical trials were presented on the opening day of the American Society of Clinical Oncology’s (ASCO) annual conference in Chicago on Friday. In some cases, immunotherapy has been shown to completely eradicate cancer.

Drug boosts long-term survival after breast cancer: study

After a diagnosis of localized breast cancer, women are often prescribed tamoxifen for five years to help prevent a recurrence, but researchers said Saturday another drug, anastrazole, may work better. The federally funded phase III study involved more than 3,100 postmenopausal women with a kind of breast cancer known as ductal carcinoma in situ, which was treated by removing the cancerous lump followed by a radiation regimen. Some women were

Pfizer's Ibrance drug slows progression of breast cancer

By Deena Beasley CHICAGO (Reuters) – A Phase III trial of Pfizer Inc’s drug Ibrance showed that, in combination with hormone therapy, the drug more than doubled the duration of disease control for women with the most common type of breast cancer. At the time of an interim analysis, patients given Ibrance in combination with AstraZeneca Plc’s Faslodex (fulvestrant), a widely used treatment to block estrogen, lived an average of

U.N. warns of coming hunger in North Korea

By Tom Miles GENEVA (Reuters) – A drought in North Korea could lead to huge food shortages this year, the top U.N. official in the country told Reuters in an interview. Rainfall in 2014, the lowest in records going back 30 years, was 40-60 percent below 2013 levels, and reservoirs are very low, said Ghulam Isaczai, the U.N. resident coordinator.